Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is a very rare genetic condition that affects growth and brain development before birth. Babies with Neu-Laxova syndrome often have severe growth restriction, a very small head, tight joints, and skin changes, and the condition is usually recognized on prenatal scans or at birth. It may help to know that doctors have studied this condition for decades, but it is still considered very severe and lifelong from the earliest stages of development. Most affected babies do not survive long before or after birth, although the exact course can vary with the severity of the condition. There is no cure, so care focuses on comfort, supportive treatment, and genetic counseling for the family.
How many people live with Neu-laxova syndrome due to phosphoserine aminotransferase deficiency?
Worldwide and U.S. estimates for Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency are not consistently reported by a single reliable source. It is extremely rare, and published medical reports describe only a very small number of affected families rather than a dependable count of how many people are living with it worldwide or in the United States.
Overview
Neu-laxova syndrome due to phosphoserine aminotransferase deficiencySymptoms
Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency causes severe growth restriction before birth. Babies often have a small head, tight or unusual skin, limb contractures, and brain and facial differences. It is recognized on prenatal ultrasound or at birth.
Outlook and prognosis
Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is a very severe genetic condition, and most affected babies die before birth or soon after delivery. In the rare longer-surviving child, outlook depends on how much the brain, skin, and growth are affected.
Causes and risk factors
Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is caused by harmful changes in the PSAT1 gene. A child is affected when both parents pass on a nonworking copy, though the change can also arise newly. There are no known lifestyle or environmental causes.
Genetic influences
Genetics are central to Neu-laxova syndrome due to phosphoserine aminotransferase deficiency. It is caused by harmful changes in the PSAT1 gene, usually inherited when both parents carry one altered copy, which is why genetic testing and family counseling matter.
Diagnosis
Diagnosis of Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency usually starts with clinical features seen before birth or at delivery. Ultrasound and other imaging can support the diagnosis. Genetic tests confirm the underlying gene change.
Treatment and drugs
Treatment for Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency centers on comfort-focused care, feeding support, and help with breathing or seizures when needed. In rare less severe cases, early L-serine, sometimes with glycine, may be tried under specialist guidance.
Symptoms
Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is usually noticed before birth or right after delivery because the baby is very small and has several major birth differences. The early features of Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency often involve growth, brain development, skin, and the position of the arms and legs. This condition is very severe, and many affected babies are stillborn or live only a short time after birth.
Growth is often severely limited during pregnancy, so the baby is much smaller than expected for gestational age. This may be seen on prenatal ultrasound and usually continues through birth.
Many babies have a head that is much smaller than expected, often because the brain has not grown normally. This can change the shape of the forehead and is linked with serious neurologic problems.
The brain often has major structural differences, and movement before birth may be reduced. If a baby survives after delivery, severe developmental problems and seizures can occur.
The skin may be tight, thick, shiny, or very scaly, sometimes looking like severe dry skin at birth. These skin findings are among the more recognizable signs of the syndrome.
How people usually first notice Neu-laxova syndrome due to phosphoserine aminotransferase deficiency?
Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is usually first noticed before birth, when ultrasound may show severe growth restriction, very little fetal movement, and major differences in brain or body development. After delivery, the first signs of Neu-Laxova syndrome often include a very small head, tight or fixed joints, swelling, and skin that looks tight, thick, or scaly, along with serious feeding or breathing problems. Because this is a rare genetic condition present from the start of development, families are not expected to spot it on their own, and it is most often recognized by the prenatal care or newborn medical team.
Types of Neu-laxova syndrome due to phosphoserine aminotransferase deficiency
No distinct types of Neu-laxova syndrome due to phosphoserine aminotransferase deficiency are widely recognized.
Can I slow down the onset of symptoms?
No. For Neu-Laxova syndrome caused by phosphoserine aminotransferase deficiency, symptoms start very early in development, often before birth, and there is no good evidence that lifestyle changes or standard medical care can meaningfully delay when they begin. Because this is a rare inherited condition rather than something driven by diet, exercise, sleep, or heart health, those steps have not been shown to prevent it or push symptoms back; research is still ongoing, and for families at risk, genetic counseling and early pregnancy testing can help with planning and early information, even though they do not stop the condition from happening.
What genetics can tell you about symptoms
In Neu-Laxova syndrome caused by phosphoserine aminotransferase deficiency, genetics can give some clues about symptoms because different changes in the PSAT1 gene can affect how much enzyme activity is left. In general, variants that greatly reduce or remove this activity are linked with a very severe form that begins before birth, with major problems in growth and brain development, while variants that leave a little activity may be associated with a broader range of severity. Even so, genetics cannot always predict the exact symptoms or how severe they will be in an individual baby.
Causes and risk factors
Neu-laxova syndrome due to phosphoserine aminotransferase deficiency is caused by harmful changes in the PSAT1 gene, which can stop the body from making enough serine. It is usually inherited, so the biggest risk is having two parents who both carry one changed copy of this gene. If both parents are carriers, each pregnancy has a 1 in 4 chance of being affected. The chance is also higher when there is a family history or when the parents are blood relatives, because the same rare gene change is more likely to be shared. Lifestyle, diet, infections, and everyday exposures are not known to cause this form of Neu-laxova syndrome, and knowing your family history is a good first step.
What are the most common causes or risk factors?
Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is caused by inheriting two nonworking copies of the PSAT1 gene, one from each parent, which keeps the body from making enough of an important substance called serine. The main risk factors are having both parents carry the same changed gene, having a family history of the condition, and parents being blood relatives, which raises the chance that both carry the same rare gene change. There are no known lifestyle, diet, or environmental causes.
Environmental and biological risk factors
Most risk factors for Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency are present from the very start of pregnancy. Clear environmental causes have not been proven. Because this condition is very rare, doctors usually look first at family and reproductive history rather than everyday exposures.
This syndrome is linked to very low activity of a key enzyme the body uses to make serine, an amino acid needed in early development. This is the main biological factor known to raise the chance of the condition.
When parents are biologically related, they are more likely to share the same rare underlying trait. That can increase the chance of Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency in a pregnancy.
If a couple has had a previous pregnancy affected by this syndrome, the chance in another pregnancy is higher than in the general population. This points to a persistent body-based risk rather than a new outside exposure.
A family history of Neu-Laxova syndrome or a closely related serine-making disorder can signal increased risk. Specialist counseling before or early in pregnancy can help clarify that risk.
Genetic risk factors
This condition starts very early in pregnancy, and the underlying cause is usually a problem in making serine, a substance needed for normal growth and brain development. In Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency, this comes from harmful changes in both copies of the PSAT1 gene. Some risk factors are inherited through our genes. The main genetic risks are having two carrier parents, a family history of the condition or carrier status, and parents who are biologically related, which raises the chance of carrying the same rare gene change.
PSAT1 changes: The direct genetic cause is harmful changes in the PSAT1 gene. This gene helps make serine, which is especially important for early brain and body development. When both gene copies do not work properly, Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency can occur.
Recessive inheritance: This condition follows an autosomal recessive pattern, which means a baby usually needs to inherit one nonworking PSAT1 copy from each parent. Parents are often healthy carriers because they still have one working copy.
Carrier parents: If both parents carry a PSAT1 change, each pregnancy has a 1 in 4, or 25%, chance of being affected. There is also a 1 in 2, or 50%, chance the child will be an unaffected carrier.
Family history: A previous affected pregnancy, an affected child, or relatives known to carry PSAT1 changes can raise the chance in a family. If you are wondering who is at risk for Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency, family history is one of the clearest clues.
Related parents: When parents are biologically related, such as cousins, they are more likely to carry the same rare PSAT1 variant. That can increase the chance of autosomal recessive conditions like Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency.
Lifestyle risk factors
Neu-laxova syndrome due to phosphoserine aminotransferase deficiency is not caused by lifestyle habits, because it results from an inherited problem in serine biosynthesis. Still, how lifestyle affects Neu-laxova syndrome due to phosphoserine aminotransferase deficiency can matter for comfort, symptom control, and complications in children who survive beyond the newborn period. The most relevant lifestyle risk factors for Neu-laxova syndrome due to phosphoserine aminotransferase deficiency are usually linked to feeding, hydration, sleep, movement, and day-to-day supportive care rather than to disease onset.
Inadequate calorie and protein intake can worsen growth failure, weakness, and poor healing in a child who already has major metabolic and developmental challenges. If oral feeding is difficult, inconsistent intake may also increase the risk of aspiration, dehydration, and hospitalizations.
For patients managed with a serine-supplemented diet, poor adherence can limit the intended metabolic support for the underlying serine deficiency. This may make seizure control, growth, or neurologic stability harder to achieve, depending on the individual child’s presentation.
Vomiting, feeding problems, or long gaps without fluids can quickly worsen lethargy, constipation, and general medical instability. Good hydration is especially important when swallowing is impaired or when illness increases fluid losses.
Irregular or poor-quality sleep can aggravate irritability, muscle tone problems, and seizure susceptibility in neurologically fragile children. A consistent sleep routine may improve day-to-day function and reduce caregiver strain.
Risk prevention
Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is a rare inherited condition, so there is no known way to prevent the syndrome itself after conception. Prevention mainly means lowering the chance of an affected pregnancy through genetic counseling and testing options, and for an affected baby it means reducing complications with close specialist care. Different people need different prevention strategies—there’s no single formula. Because this condition is very severe and often starts before birth, prevention is usually discussed before or during pregnancy rather than around early symptoms of Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency.
If this condition has happened in a family before, meeting with a genetics specialist can help clarify the chance of it happening again. This is especially useful because both parents may carry one changed gene without having symptoms themselves.
Genetic testing for the parents can show whether both carry the gene change linked to Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency. Knowing this before pregnancy can help with planning and informed reproductive choices.
Some couples may consider options such as IVF with embryo testing or the use of donor egg or donor sperm to reduce the chance of another affected pregnancy. Talk to your doctor about which preventive steps are right for you.
During pregnancy, targeted genetic testing and detailed ultrasound scans may help detect whether a fetus is affected. This does not prevent the condition itself, but it can give families clearer information and more time to plan care.
Can you prevent Neu-laxova syndrome due to phosphoserine aminotransferase deficiency?
No, you cannot fully prevent Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency, because it is a rare inherited condition that happens when a baby receives the changed gene from both parents. If this condition runs in your family, genetic counseling and carrier testing before pregnancy can help you understand the risk and your options. Some families may choose in vitro fertilization, also called IVF, with embryo testing or testing during pregnancy, but these steps cannot cure the condition once a baby has it.
Transmission
Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is not contagious, so it does not spread through contact, coughing, sex, food, or pregnancy in the way an infection can. Instead, how Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is inherited usually follows an autosomal recessive pattern, which means a baby must receive one changed gene copy from each parent.
In most families, both parents are healthy carriers and do not know they carry the change. If both parents are carriers, each pregnancy has a 25% chance of being affected, a 50% chance that the child will be an unaffected carrier, and a 25% chance that the child will inherit neither changed copy.
When to test your genes
Consider genetic testing before or early in pregnancy if you or your partner have a family history of Neu-Laxova syndrome, a previous affected pregnancy, or are blood relatives. Testing can confirm the diagnosis after ultrasound findings such as severe growth restriction or brain abnormalities and helps guide reproductive planning and prenatal care.
Diagnosis
Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is usually suspected before birth or soon after delivery because the changes are often severe and recognizable. Doctors look at growth, brain and body development, and other physical features, then use specific tests to confirm the diagnosis of Neu-Laxova syndrome. Early and accurate diagnosis can help you plan ahead with confidence.
During pregnancy, ultrasound may show very poor growth, reduced movement, too much fluid around the baby, or major brain and limb differences. These imaging findings can raise concern for a serious genetic condition and guide further testing.
After birth, doctors examine the baby for a pattern of findings such as severe growth restriction, tight or fixed joints, skin swelling, and distinctive facial features. This clinical picture can strongly suggest Neu-Laxova syndrome, although other rare conditions may look similar.
Ultrasound, CT, or MRI of the brain may be used to look for problems in brain development. These findings can support the diagnosis and help explain symptoms such as severe developmental problems or seizures.
A blood sample can be used to look for changes in the PSAT1 gene, which is the usual cause of this form of Neu-Laxova syndrome. Genetic testing is the main way to confirm the genetic diagnosis of Neu-Laxova syndrome.
How is Neu-laxova syndrome due to phosphoserine aminotransferase deficiency diagnosed?
Doctors usually suspect this form of Neu-Laxova syndrome from the pattern of severe changes seen before birth or at birth, such as very poor growth, brain and body differences on pregnancy ultrasound or other scans, and findings on a careful physical exam. They may also do blood or spinal fluid tests to look for low levels of serine, a natural substance the body needs for growth and brain development. The diagnosis is then confirmed with genetic testing that looks for a change in the PSAT1 gene, which causes this type of the condition.
Stages of Neu-laxova syndrome due to phosphoserine aminotransferase deficiency
Neu-laxova syndrome due to phosphoserine aminotransferase deficiency does not have defined progression stages. This is because it is a very rare condition that usually causes severe problems before birth or at delivery, rather than changing through clear step-by-step phases over time. Early and accurate diagnosis helps you plan ahead with confidence. Doctors usually identify it through prenatal ultrasound, findings at birth, and genetic testing to confirm the cause, so prenatal diagnosis of Neu-laxova syndrome due to phosphoserine aminotransferase deficiency is often based on both scan results and lab testing.
Outlook and prognosis
The outlook for Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is generally very poor, because the condition causes profound abnormalities of brain growth and development, skin, limbs, and other organs before birth. Most affected fetuses die during pregnancy or are stillborn, and many liveborn infants die within hours to days after delivery from the severity of their congenital malformations and respiratory failure. Survival beyond the newborn period appears to be exceptionally rare, and for those few infants who are born alive, medical care is usually intensive and supportive rather than curative. Because of the high mortality and extreme severity, counseling typically focuses on pregnancy management, expected neonatal outcomes, and recurrence risk for future pregnancies.
Long-term effects
Neu-laxova syndrome due to phosphoserine aminotransferase deficiency is usually a very severe condition from before birth, and the outlook is often poor. Many affected babies die during pregnancy or shortly after birth, while the few who survive tend to have major lifelong health needs. Long-term effects vary widely, but when survival is longer, the condition often affects growth, brain development, movement, feeding, and breathing.
The most serious long-term effect is a very high risk of death before birth or in the newborn period. For families asking about the long-term effects of Neu-laxova syndrome due to phosphoserine aminotransferase deficiency, prognosis depends greatly on how severe the brain, lung, and body changes are at birth.
Babies who survive often remain very small, with poor weight gain and slow growth over time. Head size may also stay much smaller than expected because the brain and skull developed differently before birth.
Survivors usually have severe developmental impairment and need full support for daily life. Many may not reach milestones such as sitting, walking, or speaking, or may do so only in a very limited way.
Tight joints and abnormal muscle tone can make movement very limited. Over time, this can lead to fixed limb positions, difficulty with comfort and positioning, and worsening physical disability as the child grows.
How is it to live with Neu-laxova syndrome due to phosphoserine aminotransferase deficiency?
Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is an extremely severe genetic condition that usually begins before birth, and many affected babies are stillborn or live only a short time after delivery. For the few who survive birth, daily life is typically shaped by profound medical needs, including feeding difficulties, severe developmental impairment, muscle stiffness or abnormal movements, and the need for constant hands-on care. For parents and other loved ones, this often means round-the-clock caregiving, frequent hospital visits, and intense emotional strain alongside grief, uncertainty, and difficult medical decisions.
Treatment and drugs
Treatment for Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency depends on how severely the baby is affected, but there is no cure and care is usually supportive. This often means careful monitoring during pregnancy, planning for delivery in a hospital with newborn specialists, and treatment after birth aimed at comfort, breathing, feeding, and seizures if they occur. In the small number of serine-making disorders caused by this enzyme problem, doctors may consider supplements such as L-serine, sometimes with glycine, but not every treatment works the same way for every person, and these steps may not reverse the major brain and body changes already present. For many families, treatment for Neu-Laxova syndrome also includes palliative care and clear counseling so they can understand options and make decisions that fit their goals and values.
Can you cure Neu-laxova syndrome due to phosphoserine aminotransferase deficiency?
No, there is no cure for Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency at this time. Treatment focuses on supportive care, which can help with problems like feeding, breathing, seizures, comfort, and growth, and in some cases doctors may try special supplements to raise low serine levels, but this does not cure the condition. Because this syndrome can be very severe and can vary from child to child, care is usually tailored to the child's needs.
Non-drug treatment
Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is a very severe inherited condition that affects growth and development before birth and often causes major medical needs from the start of life. Care is mainly supportive and aims to improve comfort, help with breathing and feeding, protect the skin and eyes, and support families through complex decisions. Managing this condition often means care is tailored to the baby's symptoms, overall stability, and goals of care.
Many babies with Neu-Laxova syndrome need help with breathing because of weak breathing effort, a small chest, or other serious birth differences. This may include oxygen, gentle suctioning, careful positioning, or machine support in a neonatal or intensive care setting.
Feeding can be difficult because of poor sucking, low energy, or problems with swallowing safely. Structured programs, like feeding therapy and tube feeding support, can help with nutrition and lower the risk of choking or inhaling milk into the lungs.
Comfort-focused care is often a central part of treatment, especially when symptoms are severe and survival is limited. This can include warmth, skin-to-skin holding when possible, reducing distress from procedures, and making sure the baby is as calm and comfortable as possible.
Gentle stretching, positioning, and range-of-motion therapy may help with tight joints and limited movement. Some non-drug options are delivered by specialists, and in this condition therapy is usually adapted very carefully to the baby's strength and comfort.
Your genes may have an impact on how drugs work for you
For people living with Neu-Laxova syndrome caused by phosphoserine aminotransferase deficiency, there is no well-established evidence that other inherited gene differences meaningfully change how the main treatments work. Care is usually focused on supportive treatment and, in some cases, supplements such as serine, with doctors adjusting care based on symptoms, feeding, growth, and overall comfort rather than using genetic testing to pick medicines. Because this condition is very rare and often severe, treatment response can still vary from one person to another, but this is usually linked more to how serious the condition is than to known differences in how the body handles drugs.
Pharmacological treatments
Treatment for Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is centered on replacing missing serine and easing complications, but there is no proven cure for the severe form. The main medicine-like treatment reported is L-serine, sometimes paired with glycine, because the body cannot make enough of these building blocks on its own. Medication can feel like a big step, but in this condition the biggest benefit is usually seen when treatment starts as early as possible. In many living with this disorder, especially babies with very severe disease before birth or at delivery, medicines may have limited effect and care may focus on comfort and symptom control.
L-serine is the key treatment used for serine biosynthesis disorders, including Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency. It aims to raise serine levels so the brain and other tissues have more of what they need to grow and function. In the early treatment for Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency, doctors usually tailor the dose to age, weight, and lab results.
Glycine may be added with L-serine because it is closely linked to the same metabolic pathway. Some specialists use both together when blood or spinal fluid findings suggest a broader shortage. Evidence is limited, and not everyone responds in the same way.
If seizures are present, standard anti-seizure drugs such as levetiracetam, phenobarbital, or other commonly used epilepsy medicines may be needed. These drugs do not correct the underlying metabolic problem, but they can help reduce seizure burden and improve comfort. The choice depends on the seizure type, age, and overall medical condition.
Babies and children with severe Neu-Laxova syndrome may also need medicines for pain, muscle stiffness, reflux, or breathing-related distress. These are chosen based on symptoms rather than the genetic cause itself. Doctors adjust treatment plans regularly as needs change.
Genetic influences
For families affected by Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency, the genetic cause is known: it happens when a baby inherits two changed copies of the PSAT1 gene, one from each parent. This gene helps the body make serine, an amino acid that is especially important for growth and brain development before birth, so when both copies are not working properly, development can be severely disrupted. A carrier means you hold the gene change but may not show symptoms, which is why parents are usually healthy even though they can pass the condition on. This pattern is called autosomal recessive inheritance, so with each pregnancy, two carrier parents have a 1 in 4 chance of having a child with Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency. Because the cause is inherited and specific, genetic counseling and carrier testing can help families understand future pregnancy risks and whether other relatives may also be carriers.
Is Neu-laxova syndrome due to phosphoserine aminotransferase deficiency genetic?
Genetics are central to Neu-laxova syndrome due to phosphoserine aminotransferase deficiency. It is caused by harmful changes in the PSAT1 gene, usually inherited when both parents carry one altered copy, which is why genetic testing and family counseling matter.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are common in the general population and are a normal part of human biology. Most do not directly affect health and simply reflect natural human diversity. For many genes, having a variant associated with a condition suggests a possible link rather than a definite diagnosis, especially when several genes and environmental factors play a role. In some situations, though, a single well-characterized variant in a specific gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
Because treatment options for Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency are limited, identifying the exact gene change is especially important. This condition affects the body’s ability to make enough serine, so doctors may consider L-serine, sometimes with glycine, in some related serine-deficiency disorders, but this has not been shown to reliably reverse the severe features of classic Neu-Laxova syndrome. Doctors can use your genetic information to guide whether any targeted supplements are worth discussing and to avoid expecting standard medicines to fix the underlying problem. For many babies with Neu-Laxova syndrome, care is mainly supportive, such as help with feeding, breathing, seizures, muscle stiffness, and comfort. The exact variant and how severe the condition is can shape treatment decisions, since babies affected very early in pregnancy may have fewer options than those with milder presentations. Genetics also helps families understand the chance of the condition happening again and whether testing in a future pregnancy may be available.
Interactions with other conditions
Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency is usually such a severe condition from before birth that care tends to focus on its direct effects and medical complications, rather than on well-known links with other separate diseases. Many living with Neu-Laxova syndrome have major problems with growth, brain development, skin, breathing, and feeding, and these can make common illnesses like pneumonia or bloodstream infection much more serious. Seizures, poor swallowing, and very limited movement can also increase the chance of inhaling food or saliva into the lungs, which may lead to repeated chest infections. Another important aspect is how it may link with other diseases: at this time, there are no widely recognized disease pairings unique to Neu-Laxova syndrome itself, largely because it is extremely rare and often life-limiting early in life. For families and care teams, the main concern is usually how fragile health can make routine infections or organ stress harder to recover from, rather than long-term overlap with conditions seen later in childhood or adulthood.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Neu-laxova syndrome due to phosphoserine aminotransferase deficiency?
Doctors may also consider other rare conditions that affect the body’s serine-making pathway, especially 3-phosphoglycerate dehydrogenase deficiency and phosphoserine phosphatase deficiency, because they can also cause severe growth problems before birth, a very small head, brain differences, and stiff joints. Other conditions that can sometimes look similar include fetal akinesia sequence, some severe chromosome disorders, and certain infections during pregnancy, especially when the first clues come from prenatal scans or findings at birth.
History
The history of Neu-Laxova syndrome due to phosphoserine aminotransferase deficiency began with doctors noticing a striking pattern in a small number of pregnancies and newborns. In 1971, the condition was described in the medical literature after separate reports drew attention to babies with very severe growth problems before birth and a similar group of physical findings. At that stage, doctors could recognize the syndrome by what they saw, but they did not yet know the underlying biological reason.
Over the next several years, more case reports helped confirm that this was a distinct condition rather than a random mix of unrelated birth differences. Early descriptions focused on the most severe forms, often identified during pregnancy, at birth, or shortly afterward. Because those early symptoms of Neu-Laxova syndrome were so serious, the syndrome was long considered exceptionally rare and was mainly recognized in specialist centers.
As laboratory testing improved, researchers were able to look beyond the visible features and study the body chemistry behind the condition. This led to an important shift: some cases of Neu-Laxova syndrome were linked to a problem in making serine, a substance the body needs for normal growth and brain development. In recent decades, awareness has grown that this syndrome can be part of a broader group of serine-related disorders, which helped doctors understand why severity may vary from one pregnancy or child to another.
That change in understanding mattered for families as well as for clinicians. Instead of stopping at a descriptive diagnosis based only on ultrasound findings or newborn appearance, doctors could begin to confirm the cause with more targeted testing and offer clearer counseling about what had happened. Knowing this history also helps explain why older medical papers may describe Neu-Laxova syndrome in very severe terms: they were written before modern biochemical and genetic tools made it easier to recognize related conditions and sort them more precisely.